SNDX Syndax Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 12:06
Why SNDX matters now
Syndax Pharmaceuticals, Inc. (SNDX) is a US stock in Healthcare. The latest InvestLog snapshot shows $23.49 with -5.44% on the session and $2.08B in market capitalization; recent performance reads 1-month -1.86% and YTD -9.57%.
The latest financial table shown here is Q1 2026, with revenue of $64.9M, net income of $-42.7M, and EPS of $-0.49. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -16.5%.
The latest indexable market news headline is "Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.50; recent insider activity includes Botwood Nicholas A.J. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
39.54
P/S
7.75
EV/EBITDA
-11.68
DCF Value
$14.80
FCF Yield
-16.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.0%
Operating Margin
-102.9%
Net Margin
-112.0%
ROE
-256.7%
ROA
-51.5%
ROIC
-57.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $64.9M | $-42.7M | $-0.49 |
| Q4 2025 | $68.5M | $-68.0M | $-0.78 |
| FY 2025 | $172.4M | $-285.4M | $-3.29 |
| Q3 2025 | $45.9M | $-60.7M | $-0.70 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$38.50
Target (Median)
$38.50
Target Range
$31.00 - $46.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.39
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.